Solid Biosciences Inc (NASDAQ: SLDB)’s stock price has plunge by -8.17relation to previous closing price of 5.02. Nevertheless, the company has seen a -4.55% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-03 that CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 34,550 restricted stock units (“RSUs”) to two newly hired employees.
Is It Worth Investing in Solid Biosciences Inc (NASDAQ: SLDB) Right Now?
Moreover, the 36-month beta value for SLDB is 2.26. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLDB is 56.60M and currently, short sellers hold a 14.75% of that float. On June 18, 2025, SLDB’s average trading volume was 1.55M shares.
SLDB’s Market Performance
The stock of Solid Biosciences Inc (SLDB) has seen a -4.55% decrease in the past week, with a 66.43% rise in the past month, and a -6.49% fall in the past quarter. The volatility ratio for the week is 7.96%, and the volatility levels for the past 30 days are at 6.12% for SLDB. The simple moving average for the last 20 days is 20.35% for SLDB stock, with a simple moving average of -4.20% for the last 200 days.
Analysts’ Opinion of SLDB
Many brokerage firms have already submitted their reports for SLDB stocks, with Truist repeating the rating for SLDB by listing it as a “Buy.” The predicted price for SLDB in the upcoming period, according to Truist is $16 based on the research report published on January 08, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see SLDB reach a price target of $16. The rating they have provided for SLDB stocks is “Outperform” according to the report published on December 13th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to SLDB, setting the target price at $15 in the report published on December 10th of the previous year.
SLDB Trading at 37.55% from the 50-Day Moving Average
After a stumble in the market that brought SLDB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.54% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLDB starting from Kahn Clare, who purchase 1,860 shares at the price of $5.34 back on Mar 11 ’25. After this action, Kahn Clare now owns 2,960 shares of Solid Biosciences Inc, valued at $9,924 using the latest closing price.
Bain Capital Life Sciences Inv, the 10% Owner of Solid Biosciences Inc, purchase 1,000,000 shares at $4.03 during a trade that took place back on Feb 19 ’25, which means that Bain Capital Life Sciences Inv is holding 5,034,582 shares at $4,030,000 based on the most recent closing price.
Stock Fundamentals for SLDB
The total capital return value is set at -0.45. Equity return is now at value -55.30, with -47.14 for asset returns.
Based on Solid Biosciences Inc (SLDB), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -4.51. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -807.45.
Currently, EBITDA for the company is -121.9 million with net debt to EBITDA at 1.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.89.
Conclusion
To wrap up, the performance of Solid Biosciences Inc (SLDB) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
